AlphaQuest LLC Has $254,000 Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

AlphaQuest LLC lifted its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 43.4% during the fourth quarter, HoldingsChannel reports. The firm owned 13,493 shares of the company’s stock after acquiring an additional 4,083 shares during the quarter. AlphaQuest LLC’s holdings in Pacira BioSciences were worth $254,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Amundi lifted its holdings in Pacira BioSciences by 200.8% during the 4th quarter. Amundi now owns 23,114 shares of the company’s stock valued at $429,000 after purchasing an additional 15,431 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in Pacira BioSciences by 16.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after purchasing an additional 513 shares in the last quarter. Banco Santander S.A. raised its position in shares of Pacira BioSciences by 5.8% in the fourth quarter. Banco Santander S.A. now owns 126,900 shares of the company’s stock valued at $2,391,000 after buying an additional 6,900 shares in the last quarter. Global Alpha Capital Management Ltd. raised its position in shares of Pacira BioSciences by 5.7% in the fourth quarter. Global Alpha Capital Management Ltd. now owns 39,900 shares of the company’s stock valued at $752,000 after buying an additional 2,160 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Pacira BioSciences during the fourth quarter worth approximately $190,000. 99.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Barclays upped their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and raised their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. HC Wainwright upped their price target on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Finally, Needham & Company LLC lifted their price objective on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the stock. According to MarketBeat, Pacira BioSciences presently has a consensus rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock opened at $22.87 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The firm has a market capitalization of $1.06 billion, a P/E ratio of -11.27 and a beta of 0.86. The company’s 50 day moving average price is $23.96 and its two-hundred day moving average price is $19.28.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.